Epidemiology of Shock in Contemporary Cardiac Intensive Care Units.


Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
03 2019
Historique:
entrez: 19 3 2019
pubmed: 19 3 2019
medline: 6 5 2020
Statut: ppublish

Résumé

Background Clinical investigations of shock in cardiac intensive care units (CICUs) have primarily focused on acute myocardial infarction (AMI) complicated by cardiogenic shock (AMICS). Few studies have evaluated the full spectrum of shock in contemporary CICUs. Methods and Results The Critical Care Cardiology Trials Network is a multicenter network of advanced CICUs in North America. Anytime between September 2017 and September 2018, each center (n=16) contributed a 2-month snap-shot of all consecutive medical admissions to the CICU. Data were submitted to the central coordinating center (TIMI Study Group, Boston, MA). Shock was defined as sustained systolic blood pressure <90 mm Hg with end-organ dysfunction ascribed to the hypotension. Shock type was classified by site investigators as cardiogenic, distributive, hypovolemic, or mixed. Among 3049 CICU admissions, 677 (22%) met clinical criteria for shock. Shock type was varied, with 66% assessed as cardiogenic shock (CS), 7% as distributive, 3% as hypovolemic, 20% as mixed, and 4% as unknown. Among patients with CS (n=450), 30% had AMICS, 18% had ischemic cardiomyopathy without AMI, 28% had nonischemic cardiomyopathy, and 17% had a cardiac cause other than primary myocardial dysfunction. Patients with mixed shock had cardiovascular comorbidities similar to patients with CS. The median CICU stay was 4.0 days (interquartile range [IQR], 2.5-8.1 days) for AMICS, 4.3 days (IQR, 2.1-8.5 days) for CS not related to AMI, and 5.8 days (IQR, 2.9-10.0 days) for mixed shock versus 1.9 days (IQR, 1.0-3.6) for patients without shock ( P<0.01 for each). Median Sequential Organ Failure Assessment scores were higher in patients with mixed shock (10; IQR, 6-13) versus AMICS (8; IQR, 5-11) or CS without AMI (7; IQR, 5-11; each P<0.01). In-hospital mortality rates were 36% (95% CI, 28%-45%), 31% (95% CI, 26%-36%), and 39% (95% CI, 31%-48%) in AMICS, CS without AMI, and mixed shock, respectively. Conclusions The epidemiology of shock in contemporary advanced CICUs is varied, and AMICS now represents less than one-third of all CS. Despite advanced therapies, mortality in CS and mixed shock remains high. Investigation of management strategies and new therapies to treat shock in the CICU should take this epidemiology into account.

Identifiants

pubmed: 30879324
doi: 10.1161/CIRCOUTCOMES.119.005618
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e005618

Subventions

Organisme : NHLBI NIH HHS
ID : T32 HL007604
Pays : United States

Auteurs

David D Berg (DD)

Levine Cardiac Intensive Care Unit, TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B, E.A.B., V.M.B.-Z., J.-G.P., D.A.M.).

Erin A Bohula (EA)

Levine Cardiac Intensive Care Unit, TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B, E.A.B., V.M.B.-Z., J.-G.P., D.A.M.).

Sean van Diepen (S)

Department of Critical Care and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada (S.v.D., W.T.).

Jason N Katz (JN)

Divisions of Cardiology and Pulmonary and Critical Care Medicine, University of North Carolina, Center for Heart and Vascular Care Chapel Hill (J.N.K., R.O.).

Carlos L Alviar (CL)

University of Florida, Gainesville (C.L.A.).

Vivian M Baird-Zars (VM)

Levine Cardiac Intensive Care Unit, TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B, E.A.B., V.M.B.-Z., J.-G.P., D.A.M.).

Christopher F Barnett (CF)

Department of Cardiology, MedStar Washington Hospital Center, DC (C.F.B.).

Gregory W Barsness (GW)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (G.W.B., B.T.).

James A Burke (JA)

Lehigh Valley Health Network, Allentown, PA (J.A.B., A.H., F.V.).

Paul C Cremer (PC)

Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH (P.C.C., V.M.).

Jennifer Cruz (J)

Section of Cardiology, Cooper University Hospital, Camden, NJ (J.C., S.H.).

Lori B Daniels (LB)

Sulpizio Cardiovascular Center, University of California San Diego, La Jolla (L.B.D., N.P.).

Andrew P DeFilippis (AP)

Division of Cardiovascular Medicine, Department of Medicine, University of Louisville, KY (A.D.).

Affan Haleem (A)

Lehigh Valley Health Network, Allentown, PA (J.A.B., A.H., F.V.).

Steven M Hollenberg (SM)

Section of Cardiology, Cooper University Hospital, Camden, NJ (J.C., S.H.).

James M Horowitz (JM)

New York University Langone Health (J.M.H., N.K., J.N., R.O.R.).

Norma Keller (N)

New York University Langone Health (J.M.H., N.K., J.N., R.O.R.).

Michael C Kontos (MC)

Virginia Commonwealth University, Richmond (M.C.K.).

Patrick R Lawler (PR)

Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, ON, Canada (P.R.L., C.B.O.).

Venu Menon (V)

Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH (P.C.C., V.M.).

Thomas S Metkus (TS)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (T.S.M., S.P.S.).

Jason Ng (J)

New York University Langone Health (J.M.H., N.K., J.N., R.O.R.).

Ryan Orgel (R)

Divisions of Cardiology and Pulmonary and Critical Care Medicine, University of North Carolina, Center for Heart and Vascular Care Chapel Hill (J.N.K., R.O.).

Christopher B Overgaard (CB)

Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, ON, Canada (P.R.L., C.B.O.).

Jeong-Gun Park (JG)

Levine Cardiac Intensive Care Unit, TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B, E.A.B., V.M.B.-Z., J.-G.P., D.A.M.).

Nicholas Phreaner (N)

Sulpizio Cardiovascular Center, University of California San Diego, La Jolla (L.B.D., N.P.).

Robert O Roswell (RO)

New York University Langone Health (J.M.H., N.K., J.N., R.O.R.).

Steven P Schulman (SP)

Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD (T.S.M., S.P.S.).

R Jeffrey Snell (R)

Rush University Medical Center, Chicago, IL (R.J.S.).

Michael A Solomon (MA)

Critical Care Medicine Department, National Institutes of Health Clinical Center and Cardiovascular Branch, National Heart, Lung, and Blood Institute, of the National Institutes of Health, Bethesda, MD (M.A.S.).

Bradley Ternus (B)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (G.W.B., B.T.).

Wayne Tymchak (W)

Department of Critical Care and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada (S.v.D., W.T.).

Fnu Vikram (F)

Lehigh Valley Health Network, Allentown, PA (J.A.B., A.H., F.V.).

David A Morrow (DA)

Levine Cardiac Intensive Care Unit, TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (D.D.B, E.A.B., V.M.B.-Z., J.-G.P., D.A.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH